An unusual course of COVID-19 infection with late increase in C-reactive protein (clinical case reports)
https://doi.org/10.18093/0869-0189-2020-30-5-709-714
Abstract
Clinical signs of COVID-19 infection are non-specific and diagnosis is typically based on comprehensive evaluation of the patient’s history, clinical status, radiological and laboratory findings. A common finding in COVID-19 patients is increased C-reactive protein (CRP), though in some patients, CRP remains within normal range notwithstanding the presence of other criteria of severe disease. We describe two clinical cases of COVID-19 with severe bilateral pneumonia and late increase in CRP. Similar cases re quite challenging for making the diagnosis and indicating the antiinflammatory therapy.
About the Authors
S. Yu. Chikina
I.M.Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia
Russian Federation
Russian Federation
Svetlana Yu. Chikina – Candidate of Medicine, Assistant Lecturer, Department of Pulmonology, N.V.Sklifosovskiy Institute of Clinical Medicine. SPIN: 4463-8203
ul. Trubetskaya 8, build. 2, Moscow, 119991
tel.: (916) 116-04-03
M. Yu. Brovko
I.M.Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia
Russian Federation
Russian Federation
Mikhail Yu. Brovko – Candidate of Medicine, Deputy Director for Clinical Care, E.M.Tareev Clinics University Teaching Hospital No.3. SPIN: 3389-8477
ul. Trubetskaya 8, build. 2, Moscow, 119991
tel.: (499) 248-69-66
V. V. Royuk
I.M.Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia
Russian Federation
Russian Federation
Valeriy V. Royuk – Candidate of Medicine, Hospital Chief Executive Officer, University Teaching Hospital No.1
ul. Trubetskaya 8, build. 2, Moscow, 119991
tel.: (499) 248-69-66
S. N. Avdeev
I.M.Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia
Russian Federation
Russian Federation
Sergey N. Avdeev – Doctor of Medicine, Professor, Corresponding Member of Russian Academy of Sciences, Head of Department of Pulmonology. SPIN: 1645-5524
ul. Trubetskaya 8, build. 2, Moscow, 119991
tel.: (495) 708-35-76
References
1. Ponti G., Maccaferri M., Ruini C. et al. Biomarkers associated with COVID-19 disease progression. Crit. Rev. Clin. Lab. Sci. 2020; 57 (6): 389–399. DOI: 10.1080/10408363.2020.1770685.
2. Tan C., Huang Y., Shi F. et a. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J. Med. Virol. 2020; 92 (7): 856–862. DOI: 10.1002/jmv.25871.
3. Gao Y., Li T., Han M. et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J. Med. Virol. 2020; 92 (7): 791–796. DOI: 10.1002/jmv.25770.
4. Liu F., Li L., Da Xu M. et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J. Clin. Virol. 2020; 127: 104370. DOI: 10.1016/j.jcv.2020.104370.
5. Sorayaa G.V., Ulhaq Z.S. Crucial laboratory parameters in COVID-19 diagnosis and prognosis: An updated metaanalysis. Med Clin (Barc.). 2020; 155 (4): 143–151. DOI: 10.1016/j.medcli.2020.05.017.
6. Frater J.L., Zini G., d’Onofrio G. et al. COVID-19 and the clinical hematology laboratory. Int. J. Lab. Hematol. 2020; 42 (1): 11–18. DOI: 10.1111/ijlh.13229.
7. McGonagle D., Sharif K., O’Regan A. et al. COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun. Rev. 2020; 19 (6): 102537. DOI: 10.1016/j.autrev.2020.102537.
8. Lippi G., Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin. Chem. Lab. Med. 2020; 58 (7): 1131–1134. DOI: 10.1515/cclm-2020-0198.
9. Ministry of Health of the Russian Federation. [Temporary guidelines: Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 7 (03.06.2020)]. Available at: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf (in Russian).
10. Xie H., Zhao J., Lian N. et al. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study. Liver Int. 2020; 40 (6): 1321–1326. DOI: 10.1111/liv.14449.
11. Zhang Ch., Shi L., Wang F.Sh. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol. Hepatol. 2020; 5 (5): 428–430. DOI: 10.1016/S2468-1253(20)30057-1.
12. Agarwal A., Chen A., Ravindran N. et al. gastrointestinal and liver manifestations of COVID-19. J. Clin. Exp. Hepatol. 2020; 10 (3): 263–265. DOI: 10.1016/j.jceh.2020.03.001.
13. Fan Zh., Chen L., Li J. et al. Clinical features of COVID19-related liver functional abnormality. Clin. Gastroenterol. Hepatol. 2020; 18 (7): 1561–1566. DOI: 10.1016/j.cgh.2020.04.002.
14. Duan P., Chen Y., Zhang J. et al. Clinical characteristics and mechanism of liver injury in patients with severe acute respiratory syndrome. Zhonghua Gan Zang Bing Za Zhi. 2003; 11: 493–496.
15. Cai Q., Huang D., Yu H. et al. COVID-19: Abnormal liver function tests. J. Hepatol. 2020; 73 (3): 566–574. DOI: 10.1016/j.jhep.2020.04.006.
16. Garrido I., Liberal R., Macedo G. Review article: COVID-19 and liver disease-what we know on 1st May 2020. Aliment. Pharmacol. Ther. 2020; 52 (2): 267–275. DOI: 10.1111/apt.15813.
Review
For citations:
Chikina S.Yu., Brovko M.Yu., Royuk V.V., Avdeev S.N. An unusual course of COVID-19 infection with late increase in C-reactive protein (clinical case reports). PULMONOLOGIYA. 2020;30(5):709-714. https://doi.org/10.18093/0869-0189-2020-30-5-709-714
Views:
42377
Email this article 